Algorithms applied to spatially registered multi-parametric MRI for prostate tumor volume measurement.

MRI Supervised target detection color analysis color display and psychovisual analysis (CIELAB) multi-parametric MRI (MP-MRI) prostate cancer (PCa) tumor volume measurements

Journal

Quantitative imaging in medicine and surgery
ISSN: 2223-4292
Titre abrégé: Quant Imaging Med Surg
Pays: China
ID NLM: 101577942

Informations de publication

Date de publication:
Jan 2021
Historique:
entrez: 4 1 2021
pubmed: 5 1 2021
medline: 5 1 2021
Statut: ppublish

Résumé

Prostate tumor volume correlates with critical components of cancer staging such as Gleason score (GS) grade, predicted disease progression, and metastasis. Therefore, non-invasive tumor volume measurement may elevate clinical management. Radiology assessments of multi-parametric MRI (MP-MRI) commonly visually examine individual images to determine possible tumor presence. This study combines registered MP-MRI into a single image that display normal tissue and possible lesions. This study tests and exploits the vector nature of spatially registered MP-MRI by using supervised target detection algorithms (STDA) and color display and psychovisual analysis (CIELAB) to non-invasively estimate prostate tumor volume. MRI, including T1, T2, diffusion [apparent diffusion coefficient (ADC)], dynamic contrast enhanced (DCE) images, were resampled, rescaled, translated, and stitched to form spatially registered Multi-parametric cubes. The multi-parametric or multi-spectral signatures (7-component or T1, T2, ADC, etc.) that characterize the prostate tumors were inserted into target detection algorithms with conical decision surfaces (adaptive cosine estimator, ACE). Various detection thresholds were applied to discriminate tumor from normal tissue. In addition, tumor appeared as yellow in color images that were created by assigning red to washout from DCE, green to high B from diffusion, and blue to autonomous diffusion image. The yellow voxels in the three-channel hypercube were visually identified by a reader and recording voxels that exceed a threshold in the b* component of the CIELAB algorithm. The number of reported tumor voxels were converted to volume based on spatial resolution and slice separation. The tumor volume measurements were quantitatively validated by comparing the tumor volume computations to the pathologist's assessment of the histology of sectioned whole mount prostates from 26 consecutive patients with prostate adenocarcinoma who underwent radical prostatectomy. This study analyzed tumors exceeding 1 cc and that also took up contrast material (18 patients). High correlation coefficients for tumor volume measurements using supervised target detection and color analysis Supervised target detection and color display and analysis applied to registered MP-MRI non-invasively estimates prostate tumor volumes >1 cc and displaying angiogenesis.

Sections du résumé

BACKGROUND BACKGROUND
Prostate tumor volume correlates with critical components of cancer staging such as Gleason score (GS) grade, predicted disease progression, and metastasis. Therefore, non-invasive tumor volume measurement may elevate clinical management. Radiology assessments of multi-parametric MRI (MP-MRI) commonly visually examine individual images to determine possible tumor presence. This study combines registered MP-MRI into a single image that display normal tissue and possible lesions. This study tests and exploits the vector nature of spatially registered MP-MRI by using supervised target detection algorithms (STDA) and color display and psychovisual analysis (CIELAB) to non-invasively estimate prostate tumor volume.
METHODS METHODS
MRI, including T1, T2, diffusion [apparent diffusion coefficient (ADC)], dynamic contrast enhanced (DCE) images, were resampled, rescaled, translated, and stitched to form spatially registered Multi-parametric cubes. The multi-parametric or multi-spectral signatures (7-component or T1, T2, ADC, etc.) that characterize the prostate tumors were inserted into target detection algorithms with conical decision surfaces (adaptive cosine estimator, ACE). Various detection thresholds were applied to discriminate tumor from normal tissue. In addition, tumor appeared as yellow in color images that were created by assigning red to washout from DCE, green to high B from diffusion, and blue to autonomous diffusion image. The yellow voxels in the three-channel hypercube were visually identified by a reader and recording voxels that exceed a threshold in the b* component of the CIELAB algorithm. The number of reported tumor voxels were converted to volume based on spatial resolution and slice separation. The tumor volume measurements were quantitatively validated by comparing the tumor volume computations to the pathologist's assessment of the histology of sectioned whole mount prostates from 26 consecutive patients with prostate adenocarcinoma who underwent radical prostatectomy. This study analyzed tumors exceeding 1 cc and that also took up contrast material (18 patients).
RESULTS RESULTS
High correlation coefficients for tumor volume measurements using supervised target detection and color analysis
CONCLUSIONS CONCLUSIONS
Supervised target detection and color display and analysis applied to registered MP-MRI non-invasively estimates prostate tumor volumes >1 cc and displaying angiogenesis.

Identifiants

pubmed: 33392016
doi: 10.21037/qims-20-137a
pii: qims-11-01-119
pmc: PMC7719922
doi:

Types de publication

Journal Article

Langues

eng

Pagination

119-132

Informations de copyright

2021 Quantitative Imaging in Medicine and Surgery. All rights reserved.

Déclaration de conflit d'intérêts

Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at http://dx.doi.org/10.21037/qims-20-137a). Dr. RM has a patent null pending and has submitted a non-provisional patent application related to this study and is waiting for judgement but reports no other conflicts of interest. Dr. CBS received an honorarium from Varian Medical Systems but reports no other conflicts of interest, outside the submitted work. The other authors have no conflicts of interest to declare.

Références

Urology. 2004 Jul;64(1):101-5
pubmed: 15245944
Sci Rep. 2017 Jan 23;7:41107
pubmed: 28112222
J Urol. 2011 Nov;186(5):1818-24
pubmed: 21944089
BMC Med Imaging. 2015 Aug 12;15:29
pubmed: 26263899
Eur Urol. 1997;32(2):140-9
pubmed: 9286643
AJR Am J Roentgenol. 2007 Aug;189(2):323-8
pubmed: 17646457
J Digit Imaging. 2013 Dec;26(6):1045-57
pubmed: 23884657
Prostate Cancer Prostatic Dis. 2014 Jun;17(2):144-8
pubmed: 24469091
Prostate Cancer Prostatic Dis. 2007;10(1):66-71
pubmed: 17189956
Radiology. 2009 Aug;252(2):449-57
pubmed: 19703883
Phys Med Biol. 2012 Mar 21;57(6):1527-42
pubmed: 22391091
J Urol. 1990 Jun;143(6):1155-62
pubmed: 1692886
Radiology. 2016 Jun;279(3):805-16
pubmed: 26761720
J Urol. 1990 Jun;143(6):1183-7
pubmed: 2342179
Hum Pathol. 1992 Mar;23(3):258-66
pubmed: 1555836
J Urol. 2006 Dec;176(6 Pt 1):2432-7
pubmed: 17085122
J Magn Reson Imaging. 2005 Mar;21(3):258-62
pubmed: 15723379
Radiology. 2010 Apr;255(1):89-99
pubmed: 20308447
Comput Biol Med. 2018 Nov 1;102:1-15
pubmed: 30219733
CA Cancer J Clin. 2019 Jan;69(1):7-34
pubmed: 30620402
Urology. 1993 May;41(5):403-11
pubmed: 8488608
Eur Urol. 1999 Jan;35(1):32-5
pubmed: 9933792
Radiology. 1989 Dec;173(3):847-51
pubmed: 2479050
J Urol. 1993 Jun;149(6):1478-81
pubmed: 8501792
J Magn Reson Imaging. 2008 Jan;27(1):132-9
pubmed: 18050334
Int J Mol Sci. 2017 Feb 24;18(3):
pubmed: 28245570
J Urol. 2004 Aug;172(2):508-11
pubmed: 15247716
Proc Natl Acad Sci U S A. 2015 Nov 17;112(46):E6265-73
pubmed: 26578786
J Urol. 2017 Feb;197(2):320-326
pubmed: 27484386
Radiology. 2015 Apr;275(1):144-54
pubmed: 25423145
Comput Biol Med. 2018 May 1;96:252-265
pubmed: 29653354
AJR Am J Roentgenol. 1993 Jul;161(1):81-6
pubmed: 8517328
Eur Urol. 2006 Dec;50(6):1163-74; discussion 1175
pubmed: 16842903
Rev Sci Instrum. 2009 Oct;80(10):104301
pubmed: 19895076
Br J Radiol. 2007 Feb;80(950):90-5
pubmed: 17303616
Phys Med Biol. 2010 Mar 21;55(6):1719-34
pubmed: 20197602
J Urol. 2012 Oct;188(4):1157-1163
pubmed: 22901591
J Comput Assist Tomogr. 2005 Mar-Apr;29(2):149-53
pubmed: 15772529
Virchows Arch. 2006 Sep;449(3):297-301
pubmed: 16909262
NMR Biomed. 2012 Apr;25(4):607-19
pubmed: 21960175
Radiology. 2002 Apr;223(1):91-7
pubmed: 11930052
J Urol. 1996 Jan;155(1):232-7
pubmed: 7490842
Urology. 1997 Mar;49(3):385-91
pubmed: 9123703
J Magn Reson Imaging. 1999 Sep;10(3):223-32
pubmed: 10508281
Infect Agent Cancer. 2017 Oct 30;12:57
pubmed: 29093748
Cancer. 1990 Sep 15;66(6):1225-33
pubmed: 2400973
AJR Am J Roentgenol. 1996 Apr;166(4):845-52
pubmed: 8610561
J Magn Reson Imaging. 2012 Jul;36(1):213-24
pubmed: 22337003
Comput Biol Med. 2018 Mar 1;94:65-73
pubmed: 29407999

Auteurs

Rulon Mayer (R)

Oncoscore, Garrett Park, MD, USA.
University of Pennsylvania, Philadelphia, PA, USA.

Charles B Simone (CB)

New York Proton Center, New York, NY, USA.

Baris Turkbey (B)

National Institutes of Health, Bethesda, MD, USA.

Peter Choyke (P)

National Institutes of Health, Bethesda, MD, USA.

Classifications MeSH